150 related articles for article (PubMed ID: 25151801)
1. [Lung cancer: progress in diagnosis and treatments. Topics: IV. Recent topics; 1. Driver mutations in non-small cell lung cancer].
Mano H
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1355-9. PubMed ID: 25151801
[No Abstract] [Full Text] [Related]
2. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
Maemondo M
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
[No Abstract] [Full Text] [Related]
3. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
4. Correlation between adverse events after drug treatment and the
Luo H; Qin G; Yao C
J Int Med Res; 2019 Aug; 47(8):3522-3533. PubMed ID: 31315482
[TBL] [Abstract][Full Text] [Related]
5. EGFR mutations in Asian patients with advanced lung adenocarcinoma.
Liam CK; Pang YK; Poh ME
J Thorac Oncol; 2014 Sep; 9(9):e70-1. PubMed ID: 25122441
[No Abstract] [Full Text] [Related]
6. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.
Wang R; Zhang Y; Pan Y; Li Y; Hu H; Cai D; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
Oncotarget; 2015 Oct; 6(33):34300-8. PubMed ID: 26486077
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
Moore DA; Balbi KJ; Poskitt B; Bennett P
J Clin Pathol; 2022 Mar; 75(3):209-210. PubMed ID: 34168072
[No Abstract] [Full Text] [Related]
8. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
9. [Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Sun L; Xiong Z; Han C
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):129-138. PubMed ID: 29526181
[TBL] [Abstract][Full Text] [Related]
10. EML4-ALK: honing in on a new target in non-small-cell lung cancer.
Horn L; Pao W
J Clin Oncol; 2009 Sep; 27(26):4232-5. PubMed ID: 19667260
[No Abstract] [Full Text] [Related]
11. Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 May; 6(6):338-9. PubMed ID: 15943892
[No Abstract] [Full Text] [Related]
12. In response.
Shi Y; Yang PC
J Thorac Oncol; 2014 Jul; 9(7):e58-e59. PubMed ID: 24926559
[No Abstract] [Full Text] [Related]
13. To the editor.
Ou SI
J Thorac Oncol; 2014 Jul; 9(7):e57-e58. PubMed ID: 24926558
[No Abstract] [Full Text] [Related]
14. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY; Ke EE; Yang JJ; Sun YL; Yan HH; Zheng MY; Bai XY; Wang Z; Su J; Chen ZH; Zhang XC; Dong ZY; Wu SP; Jiang BY; Chen HJ; Wang BC; Xu CR; Zhou Q; Mei P; Luo DL; Zhong WZ; Yang XN; Wu YL
Lung Cancer; 2017 Dec; 114():96-102. PubMed ID: 29173773
[TBL] [Abstract][Full Text] [Related]
15. De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.
Thai A; Chia PL; Russell PA; Do H; Dobrovic A; Mitchell P; John T
Intern Med J; 2017 Sep; 47(9):1071-1074. PubMed ID: 28891180
[TBL] [Abstract][Full Text] [Related]
16. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
17. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.
Salto-Tellez M; Tsao MS; Shih JY; Thongprasert S; Lu S; Chang GC; Au JS; Chou TY; Lee JS; Shi YK; Radzi A; Kang JH; Kim SW; Tan SY; Yang JC
J Thorac Oncol; 2011 Oct; 6(10):1663-9. PubMed ID: 21869714
[TBL] [Abstract][Full Text] [Related]
18. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
Reck M; Rabe KF
N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
[No Abstract] [Full Text] [Related]
19. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
20. Perspectives in Lung Cancer--Third Asian-pacific Conference. 11-12 September 2009, Bangkok, Thailand.
Lopes Gde L
IDrugs; 2009 Nov; 12(11):689-91. PubMed ID: 19844853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
